Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PolyA RNA-seq from iPSCs and differentiated iPSCs treated with Nutlin-3

ABSTRACT: Analysis of steady-state mRNA levels in induced pluripotent stem cells (iPSCs), iPSCs differentiated for 5 days with retinoic acid (RA) (5d-RAI), and iPSCs differentiated to cardiomyocytes (CM), and treated with DMSO (vehicle) or the p53 inhibitor Nutlin-3.

ORGANISM(S): Homo sapiens

PROVIDER: GSE207376 | GEO | 2022/11/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PolyA RNA-seq from iPSCs and differentiated iPSCs treated with Nutlin-3

Project description:PolyA RNA-seq from iPSCs and differentiated iPSCs treated with Nutlin-3

| PRJNA854947 | ENA

PolyA RNA-seq from differentiated iPSCs

Project description:PolyA RNA-seq from differentiated iPSCs

| PRJNA854943 | ENA

Human iPSCs differentiated into SMCs

Project description:Human iPSCs were differentiated towards an induced-SMC (iSMC) phenotype in a 10-day protocol. Proteomics was performed throughout the entire differentiation time course to provide a robust, well-defined starting and ending cell population. Proteomics data verified iPSC differentiation to iSMCs. Proteomics comparison with primary human SMCs showed a high correlation with iSMCs. After iSMC differentiation, we initiated calcification in the iSMCs by culturing the cells in osteogenic media for 17 days.

2022-10-14 | PXD032353 | Pride

Impact of regulatory variation across human iPSCs and differentiated cells [ATAC-seq iPSC-CM]

Project description:Impact of regulatory variation across human iPSCs and differentiated cells [ATAC-seq iPSC-CM]

| PRJNA427322 | ENA

Global gene expression analysis in macrophages treated with Nutlin-3

Project description:The goal of the study is to identify p53 target genes specific to macrophages using the p53 stabilizer, Nutlin-3. Macrophages were differentiated x-vivo from monocytes obtained from healthy volunteers either left untreated or treated for 2 hours with 100 ng/mL of lipopolysaccharide (LPS), 0.1%v/v of DMSO (vehicle control for Nutlin-3) or 10 micromolar Nutlin-3. Three replicates were included for each treatment group.

2014-05-21 | E-GEOD-43596 | biostudies-arrayexpress

PolyA RNA-seq from retinoic acid-differentiated iPSCs treated with GSK343, 5-aza, or Combo (GSK343 & 5-aza)

Project description:Analysis of steady-state mRNA levels in induced pluripotent stem cells (iPSCs) differentiated for 5 days with retinoic acid (RA) and treated for final 48 hrs with GSK343 (EZH2 inhibitor), 5-azacytidine (5-aza, DNA methyltransferase inhibitor), or their combination (Combo).

2022-11-08 | GSE207375 | GEO

PolyA RNA-seq from CHP212 WT and FAM193AKO cells treated with Nutlin-3

Project description:Analysis of steady-state mRNA levels in CHP212 WT and FAM193AKO cells following DMSO or Nutlin-3a treatment.

2022-12-19 | GSE189133 | GEO

Impact of regulatory variation across human iPSCs and differentiated cells

Project description:Impact of regulatory variation across human iPSCs and differentiated cells

| PRJNA354301 | ENA

Human iPSCs are differentiated into the cell types constituting the BBB

Project description:We used a well-established protocol for each cell type for differentiating iPSCs into brain endothelial cells (iECs), pericytes (iPCs), and astrocytes (iASs), and then validated the identity of each differentiated cell using RNA sequencing.

2023-11-22 | GSE220105 | GEO

Efficacy of trametinib and dabrafenib associated with radioactive iodine for the treatment of refractory metastatic differentiated thyroid cancer

Project description:Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RAS or BRAFV600E mutation. To evaluate the objective response rate according to RECIST criteria in thyroid cancer patients with metastatic radioactive iodine (RAI) refractory disease, 6 months after a treatment combining in each arm of the phase II trial (patients with RAS mutation or patients with BRAFV600E mutation): - Arm A: 6 weeks of trametinib followed by RAI treatment (5.5 GBq following rhTSH) in patients with RAS mutation - Arm B: 6 weeks of trametinib plus dabrafenib followed by RAI treatment (5.5 GBq following rhTSH) in patients with BRAFV600E mutation

2023-09-01 | E-MTAB-12837 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data